AbbVie (ABBV) announced the European Commission, or EC, granted marketing authorization for Elahere for the treatment of adult patients with folate receptor-alpha, or FRa, positive, platinum-resistant high grade serous epithelial ovarian, fallopian tube or primary peritoneal cancer who have received one to three prior systemic treatment regimens. Elahere is the first and only folate receptor alpha-directed antibody drug conjugate medicine approved in the European Union, as well as Iceland, Liechtenstein, Norway, and Northern Ireland.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABBV:
- Wolfe starts AbbVie at Outperform, says valuation an attractive entry point
- AbbVie initiated with an Outperform at Wolfe Research
- JPMorgan trims AbbVie target, removes from Analyst Focus List
- Elliott confirms big Honeywell stake, Home Deport reports Q3 beat: Morning Buzz
- Bristol Myers price target raised to $61 from $57 at BMO Capital